Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to -$33.3 million.

  • UroGen Pharma's Consolidated Net Income fell 4086.51% to -$33.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$164.6 million, marking a year-over-year decrease of 4269.79%. This contributed to the annual value of -$126.9 million for FY2024, which is 2408.94% down from last year.
  • UroGen Pharma's Consolidated Net Income amounted to -$33.3 million in Q3 2025, which was down 4086.51% from -$49.9 million recorded in Q2 2025.
  • UroGen Pharma's 5-year Consolidated Net Income high stood at -$21.9 million for Q3 2023, and its period low was -$49.9 million during Q2 2025.
  • In the last 5 years, UroGen Pharma's Consolidated Net Income had a median value of -$28.5 million in 2021 and averaged -$30.4 million.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first skyrocketed by 1635.46% in 2021, then tumbled by 4950.75% in 2025.
  • Over the past 5 years, UroGen Pharma's Consolidated Net Income (Quarter) stood at -$28.5 million in 2021, then dropped by 1.47% to -$28.9 million in 2022, then grew by 9.88% to -$26.0 million in 2023, then plummeted by 44.19% to -$37.5 million in 2024, then grew by 11.1% to -$33.3 million in 2025.
  • Its Consolidated Net Income stands at -$33.3 million for Q3 2025, versus -$49.9 million for Q2 2025 and -$43.8 million for Q1 2025.